menu
    • menu
    [{"orgOrder":0,"company":"Oculis","sponsor":"Neurotrials","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oculis \/ Neurotrials","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Neurotrials"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Simbec Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Accure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accure Therapeutics \/ Simbec Research","highestDevelopmentStatusID":"6","companyTruncated":"Accure Therapeutics \/ Simbec Research"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BofA Securities"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Privosegtor

    Menu

    Privosegtor

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

                            Details : Oculis intends to use the net proceeds from the Offering to advance and accelerate its clinical development pipeline, which include Privosegtor (OCS-05) is being evaluated for acute optic neuritis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oculis’ OCS-05 Meets Key Endpoints in Phase 2 Acute Optic Neuritis Trial

                            Details : OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator. It is being evaluated for the treatment of patients with acute optic neuritis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oculis Completes Enrollment in Phase 2 ACUITY Trial with OCS-05 for Acute Optic Neuritis

                            Details : OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator. It is being evaluated for the treatment of patients with acute optic neuritis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 08, 2024

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Oculis

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Neurotrials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OCS-05 in Patients with Acute Optic Neuritis

                            Details : OCS-05 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Optic Neuritis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Neurotrials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Accure Therapeutics

                            Spain arrow
                            AAPS
                            Not Confirmed

                            Accure Therapeutics

                            Spain arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Simbec Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BN201 SAD MAD Study in Healthy Subjects

                            Details : BN201 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Optic Neuritis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 15, 2018

                            Lead Product(s) : Privosegtor

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Simbec Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth